Anti-Hu CD164 Purified Monoclonal Antibody

CD164, also known as endolyn, is a type I transmembrane protein with heavily glycosylated extracellular part containing sialic acid and glycosaminoglycan residues. CD164 plays both adhesive and antiadhesive role and serves as a potent negative regulator for CD34+ CD38- hematopoietic progenitor cell proliferation. It has also been reported to be involved in myogenic differentiation and cancer metastasis. The adhesive and negative regulatory functions seem to depend on different posttranslational modifications of CD164 protein.

Breast tumor cell line T-47D. The mouse monoclonal antibody 67D2 recognizes an extracellular class III epitope (not sensitive to sialidase, N-glycanase, O-glycosidase, and O-sialoglycoprotease) of CD164, a sialomucin expressed in hematopoietic myeloid and erythroid progenitors, activated basophils, and in various carcinomas and leukemic cells.

Isoform 1 and isoform 3 are expressed in hematopoietic and non-hematopoietic tissues. Isoform 1 is expressed by prostate cancer tumors and prostate cancer cell lines. The expression is greater in bone metastases than in primary tumors. Expression in osseous metastasis is greater than that in soft tissue metastasis. Isoform 2 is expressed in the small intestine, colon, lung, thyroid and in colorectal and pancreatic adenocarcinoma. Isoform 4 is expressed by both hematopoietic progenitor cells and bone marrow stromal cells.

Sialomucin that may play a key role in hematopoiesis by facilitating the adhesion of CD34 (+) cells to the stroma and by negatively regulating CD34 (+) CD38 (lo/-) cell proliferation. Modulates the migration of umbilical cord blood CD133+ cells and this is mediated through the CXCL12/CXCR4 axis. May play an important role in prostate cancer metastasis and the infiltration of bone marrow by cancer cells. Promotes myogenesis by enhancing CXCR4-dependent cell motility. Positively regulates myoblast migration and promotes myoblast fusion into myotubes (By similarity) .